CCM
PASG icon

Cinctive Capital Management’s Passage Bio PASG Stock Holding History

Cinctive Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,074
Closed -$338K – 302
2020
Q1 		$338K Buy
+1,074
New +$336K 0.08% 196

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cinctive Capital Management's PASG Position: Q2 2020 in Review

Cinctive Capital Management sold out of Passage Bio (PASG) in Q2 2020, closing a stake of 1,074 shares — an estimated $338K sold.

Cinctive Capital Management first reported a position in PASG in Q1 2020 and held it in 1 quarter. The position peaked at $338K in Q1 2020. 66 funds tracked by Wall St. Rank hold PASG as of Q2 2020.

  • Cinctive Capital Management reported no remaining Passage Bio position as of Q2 2020 after selling out during the quarter.
  • Cinctive Capital Management sold 1,074 Passage Bio shares in Q2 2020, an estimated $338K.
  • Cinctive Capital Management first reported a position in Passage Bio in Q1 2020 and held it in 1 quarter.
  • Cinctive Capital Management's Passage Bio position peaked at $338K in Q1 2020.
  • 66 funds tracked by Wall St. Rank held Passage Bio as of Q2 2020.

Based on Cinctive Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.